SCHEMBL1102190

SCHEMBL1102190

CCCCc1ccc(-c2ccc3c4c([nH]c3c2)-c2cc(C(N)=O)ccc2C4)cc1

nearest known ligand 0.89

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
MPL P40238 19/20 0.89
RARB P10826 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1092004 0.85 MPL (1.00) MPL
SCHEMBL1091005 0.85 MPL (1.00) MPLRARB
SCHEMBL1091786 0.77 MPL (1.00) MPLRARB
SCHEMBL1102183 0.74 MPL (1.00) MPL
SCHEMBL1091245 0.74 MPL (0.81) MPL
SCHEMBL1102150 0.73 MPL (1.00) MPL
SCHEMBL1102147 0.72 MPL (1.00) MPLRARB
SCHEMBL15750344 0.71 RARB (0.72) MPLRARB
SCHEMBL1091888 0.70 MPL (0.89) MPLRARB
SCHEMBL1102138 0.69 MPL (0.65) MPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153671-B2 Heterotetracyclic compounds as TPO mimetics IRM LLC (BM) 2012-04-10 US disclosed
EP-1910338-B1 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS IRM LLC (BM) 2010-08-25 EP disclosed
US-20090075996-A1 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS IRM LLC (BM) 2009-03-19 US disclosed
WO-2007009120-A2 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS IRM LLC (BM) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090075996-A1 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS MPL, TPO, THPO MPL 1/4885RARB 1854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.